Selective small-molecule inhibitor reveals critical mitotic functions of human CDK1
Top Cited Papers
- 11 July 2006
- journal article
- research article
- Published by Proceedings of the National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 103 (28) , 10660-10665
- https://doi.org/10.1073/pnas.0600447103
Abstract
CDK1 is a nonredundant cyclin-dependent kinase (CDK) with an essential role in mitosis, but its multiple functions still are poorly understood at a molecular level. Here we identify a selective small-molecule inhibitor of CDK1 that reversibly arrests human cells at the G2/M border of the cell cycle and allows for effective cell synchronization in early mitosis. Inhibition of CDK1 during cell division revealed that its activity is necessary and sufficient for maintaining the mitotic state of the cells, preventing replication origin licensing and premature cytokinesis. Although CDK1 inhibition for up to 24 h is well tolerated, longer exposure to the inhibitor induces apoptosis in tumor cells, suggesting that selective CDK1 inhibitors may have utility in cancer therapy.Keywords
This publication has 31 references indexed in Scilit:
- Activation of p53 by MDM2 Antagonists Can Protect Proliferating Cells from Mitotic InhibitorsCancer Research, 2005
- Origin recognition and the chromosome cycleFEBS Letters, 2004
- In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2Science, 2004
- Recycling the Cell CycleCell, 2004
- Targets of the cyclin-dependent kinase Cdk1Nature, 2003
- The ‘ORC cycle’: a novel pathway for regulating eukaryotic DNA replicationGene, 2003
- Cell Cycle Control of DNA ReplicationScience, 1996
- How Proteolysis Drives the Cell CycleScience, 1996
- Principles of CDK regulationNature, 1995
- Cyclin-dependent kinases: regulators of the cell cycle and moreChemistry & Biology, 1994